Grünwald V - Search Results

1

Practical management of everolimus-related toxicities in patients with advanced solid tumors.

Grünwald V, Weikert S, Pavel ME, Hörsch D, Lüftner D, Janni W, Geberth M, Weber MM. Grünwald V, et al. Onkologie. 2013;36(5):295-302. doi: 10.1159/000350625. Epub 2013 Apr 5. Onkologie. 2013. PMID: 23689226 Review.

2

Acral necrosis after inadequate excessive administration of bleomycin in a testicular cancer patient.

Grünwald V, Bolte O, Wiebe S, Ganser A, Schöffski P. Grünwald V, et al. Onkologie. 2005 Jan;28(1):41-3. doi: 10.1159/000082054. Onkologie. 2005. PMID: 15591723

3

Managing side effects of angiogenesis inhibitors in renal cell carcinoma.

Grünwald V, Heinzer H, Fiedler W. Grünwald V, et al. Onkologie. 2007 Oct;30(10):519-24. doi: 10.1159/000107721. Epub 2007 Sep 21. Onkologie. 2007. PMID: 17890892 Review.

4

Molecular targeted therapies for solid tumors: management of side effects.

Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J. Grünwald V, et al. Onkologie. 2009 Mar;32(3):129-38. doi: 10.1159/000194949. Epub 2009 Feb 16. Onkologie. 2009. PMID: 19295254 Review.

5

Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.

Seidel C, Fenner M, Reuter C, Merseburger AS, Ganser A, Grünwald V. Seidel C, et al. Among authors: grunwald v. Onkologie. 2011;34(3):111-4. doi: 10.1159/000324668. Epub 2011 Feb 15. Onkologie. 2011. PMID: 21358215

6

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.

Weikert S, Kempkensteffen C, Busch J, Johannsen M, Grünwald V, Zimmermann K, Flörcken A, Westermann J, Weinkauf L, Miller K, Keilholz U. Weikert S, et al. Among authors: grunwald v. World J Urol. 2013 Aug;31(4):805-9. doi: 10.1007/s00345-011-0676-1. Epub 2011 Apr 22. World J Urol. 2013. PMID: 21512806

7

[Use of mTOR-inhibitors in solid tumors].

Seidel C, Grünwald V. Seidel C, et al. Among authors: grunwald v. Med Monatsschr Pharm. 2011 Apr;34(4):116-26; quiz 127-8. Med Monatsschr Pharm. 2011. PMID: 21528529 Review. German.

8

Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.

Grünwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, Reuter C, Ganser A, Johannsen M. Grünwald V, et al. Onkologie. 2011;34(6):310-4. doi: 10.1159/000328575. Epub 2011 May 6. Onkologie. 2011. PMID: 21625184

9

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.

Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V. Busch J, et al. Among authors: grunwald v. BMC Cancer. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295. BMC Cancer. 2011. PMID: 21756335 Free PMC article.

10

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.

Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S. Busch J, et al. Among authors: grunwald v. Eur Urol. 2011 Dec;60(6):1163-70. doi: 10.1016/j.eururo.2011.07.037. Epub 2011 Jul 21. Eur Urol. 2011. PMID: 21802830

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

288 results

Search Page

Filters